A newly developed blood test is 96% accurate in the early detection of Alzheimer's disease.
Examining microRNA from a simple blood test can help determine whether your child is getting enough sleep.
A new blood test for Alzheimer's disease is up-to 94% accurate at predicting dementia before symptoms appear. The test's accuracy is increased when genetic predisposition and age are taken into account. The new test may eventually replace PET neuroimaging, currently considered the gold standard, for early detection of Alzheimer's.
Researchers have developed a blood test that looks at genetic markers to detect which babies who were deprived of oxygen at birth are at risk of developing neurodevelopment problems.
A new blood test could help doctors monitor those who are at risk of developing psychiatric disorders. The test looks for specific protein biomarkers in blood samples of those with risk factors for psychiatric illnesses and can help to predict who is most likely to develop psychosis in the future.
Researchers report a new blood test can help detect neurological damage associated with Alzheimer's disease before any of the cognitive symptoms appear. Additionally, researchers report the test may be applied to help identify brain damage associated with TBI, stroke and multiple sclerosis.
Higher baseline levels of N-terminal fragment of tau in the blood of healthy subjects was associated with an increased risk of developing cognitive deficits and Alzheimer's disease later in life.
Researchers have devised a new blood test that can detect if amyloid had begun to accumulate in the brain. The test help physicians diagnose Alzheimer's disease in a cheaper, less invasive way than currently available. The researchers will present their findings at the Alzheimer's Association International Conference in London.
Researchers have identified a specific group of circulating tumor cells in the blood stream of patients with breast cancer brain metastases. The finding is helping researchers to develop a new blood test to identify breast cancer patients at risk of developing brain metastasis.
A new blood test can help predict which patients with multiple sclerosis will see a decline in their condition over 12 months. The test looks for a biomarker called neurofilament light chain, a protein that can be detected as nerve cells die. People with higher levels of the protein were 40-70% more likely to experience worsening symptoms over a year than those with lower levels.